Apple Unveils Enhanced Apple Intelligence and Next-Generation Siri at WWDC 2026 
ECB Keeps July Rate Options Open Amid Iran War Energy Price Risks 
Trump Signals Opposition to USMCA Renewal as U.S. Reviews Trade Relations with Canada and Mexico 
US Dollar Edges Higher as Inflation Data and Middle East Tensions Shape Market Sentiment 
Changchun Targets EV Growth as China’s Auto Industry Consolidation Accelerates 
Coupang Hit With Record $409 Million Fine Over Data Breach Affecting 33 Million Users 
oOh!media Takeover Battle Intensifies as Bain Capital Joins Competing Bids 
Japan Producer Prices Surge in May, Strengthening Expectations of BOJ Rate Hike 
Kremlin Says New EU Sanctions Won’t Hurt Russian Banks 
US Stock Futures Rally as U.S.-Iran Peace Talks Boost Market Sentiment Despite Ongoing Strikes 
Asian Stocks Slide as Tech Selloff Deepens and US-Iran Conflict Escalates 
SpaceX IPO Sets Record With $75 Billion Raise, Valuation Hits $1.77 Trillion 
GM and Peak Energy Partner to Advance Sodium-Ion Battery Technology for Grid Storage 
Asian Currencies Mixed as Dollar Slips on Iran Peace Hopes and Fed Rate Outlook 
OpenAI Eyes Massive 10GW Ohio Data Center Campus in Potential $500 Billion AI Infrastructure Deal 
Astera Labs and Rocket Lab Surge After Nasdaq-100 Inclusion Announcement 
Pakistan Economy Grows 3.7% in FY2026 Amid Strong Fiscal Performance 
Samsung Biologics and Novartis International AG signed a contract manufacturing organization deal, and this was announced on Tuesday, June 7. The deal is worth $81 million.
According to The Korea Herald, the South Korean biotech company signed an intent letter for the CMO with the Swiss multinational pharmaceutical corporation. The agreement was announced via Samsung Biologics’ regulatory filing that also revealed that the companies signed the initial contract late last week.
Based on the report, the amount of the contract is equivalent to 6.41% of Samsung Biologics’ annual sales last year, which reached KRW1.57 trillion or around $1.25 billion. Then again, it was not mentioned which of Novartis’ biopharmaceutical products Samsung Biologics is producing under the CMO agreement.
The Korean biotech firm said that it would be releasing more deals in the future after both parties signed the main contract for their CMO partnership. The collab is said to be the first time Samsung Biologics is securing a deal from the Swiss pharmaceutical company.
“The letter of intent was the first contract between the two firms,” an official of Samsung Biologics stated. “We look forward to continuing to have cooperative relations through this deal in the future.”
The Korea Economic Daily reported that the latest deal increased Samsung Biologics’ total for CMO contracts to $400 million. The company has so far won orders from other multinational pharma firms such as GSK plc that is formerly known as GlaxoSmithKline plc, and Eli Lilly & Co. this year. In comparison, the firm was able to secure $1 billion worth of CMO contracts in 2021.
The South Korean CMO drugmaker obtained contracts from the top pharmaceutical firms in the world, including Bristol Myers Squibb, Roche, Johnson & Johnson, and Merck & Co. It was added that Samsung Biologics also has a contract with Gilead Sciences Inc. in the US.
Meanwhile, Samsung Biologics has been mostly manufacturing antibody treatments recently instead of cell-gene therapy (CGT). It has built up production facilities to make the drug substance for the messenger ribonucleic acid (mRNA)-based COVID-19 vaccines in its plant.
